Ratings by Guggenheim (Bradley Canino)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/12/2026 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 3/24/2026 | Pyxis Oncology Inc. | PYXS | Maintain | Buy (Buy) |
|
Details | ||
| 12/3/2025 | Black Diamond Therapeutics | BDTX | Downgrade | Neutral (Buy) |
3.45 (1.79) |
-48.12% | Details | |
| 11/4/2025 | Pyxis Oncology Inc. | PYXS | Maintain | Buy (N/A) |
|
Details | ||
| 9/4/2025 | Pyxis Oncology Inc. | PYXS | New Coverage | Buy (N/A) |
1.33 (2.36) |
77.44% | Details | |
| 9/4/2025 | Syndax Pharmaceuticals | SNDX | New Coverage | Buy (N/A) |
16.12 (22.80) |
41.44% | Details | |
| 9/4/2025 | Black Diamond Therapeutics | BDTX | New Coverage | Buy (N/A) |
2.80 (3.45) |
23.21% | Details |
